SCHLESINGER GROUP BRANDS ITS CLINICAL DIVISION AS SCHLESINGER CLINICAL RESEARCH

Schlesinger Group, a leading international data collection and research services company, has added Schlesinger Clinical Research, a clinical data collection services provider to its suite of brands following its substantial growth in the discipline.

Schlesinger Clinical Research addresses an unmet need in the market by encompassing all data collection aspects necessary for clinical research under one roof. The company boasts thirty proprietary sites and expert team with principal investigation experience, as well as CITI-certification in Good Clinical Practice and Human Subjects Protection to ensure adherence to study protocols.

Schlesinger Clinical Research offers a single point of contact to oversee the recruitment and consistent application of clinical study research protocols nationwide. The company specializes in Rx-to-OTC and Non-Rx product research that often involves IRB approval and FDA submissions. Schlesinger Clinical Research has worked with many of the world’s largest universities, CROs, CPG, pharma, and insight companies.

As an approved government vendor and fully FDA CFR Part-11 compliant, the company is currently supporting electronic nicotine delivery system (ENDS) manufacturers who are seeking a partner to streamline their clinical testing to meet the September 9th submission deadline for the FDA Premarket Tobacco-Product Applications (PMTA).

The addition of Schlesinger Clinical Research adds high quality regulated research to Schlesinger Group’s portfolio of capabilities, and underscore its position as the world's most comprehensive data collection and research services provider.

Commenting on the news, Rob Ramirez, EVP, Schlesinger Group, said, “This offering stands to revolutionize clinical research outcomes for clients through streamlining the research process by bringing site selection, subject enrolment, and study execution expertise under one partner.”

SCHLESINGER GROUP

Schlesinger Group is a leading data collection company offering a broad range of qualitative and quantitative solutions worldwide and delivering high-quality recruitment and research services for any methodology. Its recent acquisition of 20|20 Research has brought a unique suite of in-house online qualitative research platforms to its offering. Schlesinger Group has research offices in the US, UK, France, Spain, Germany, and India. Schlesinger’s reach coverage is global, and the company leverages automation and the high API panel connectivity capabilities of recently acquired Market Cube.

Main Executives

Steve Schlesinger, CEO & Mike Sullivan, President

Schlesinger Clinical Research Web Page

https://www.schlesingergroup.com/en/solutions/clinical-research/

Schlesinger Group Company Brands

Schlesinger Qualitative                                  Market Cube (Acquired 2020)

Schlesinger Quantitative                                20|20 Research (Acquired 2020)

Schlesinger Europe                                         Focus Pointe Global (Acquired 2109 - now Schlesinger Group)

Schlesinger Clinical Research                       Vigie Pharma (Acquired 2015)

Schlesinger Transcription Services               IVP Research labs

Schlesinger Trial & Jury Consulting              Everyone Talks

Advisors by Schlesinger

Schlesinger Group Focus Group Facilities in USA

Atlanta  Baltimore  Boston  Charlotte  Chicago  Columbus  Dallas  Houston  Kansas City  Los Angeles  Miami  Minneapolis  Nashville  New Jersey  New York  Orlando  Philadelphia  Philadelphia Bala Cynwyd  Phoenix  San Francisco  St. Louis

Research Offices and Focus Group Facilities in Europe

Schmiedl Marktforschung GmbH, Berlin  Frankfurt  Munich  Hamburg

The Research House, Central London  Wimbledon

Passerelles & ConsuMed Research, Paris

BDI Research, Barcelona  Madrid